Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.
The U.S. Health Resources and Services Administration posted Dermavant’s notice to 340B covered entities last week. The company, a subsidiary of Roivant Sciences, began selling Vtama in May 2022. It said it discovered that some entities may have bought Vtama at wholesaler acquisition price rather than at the 340B ceiling price from Q2 2022 through Q1 2023.
Dermavant said it contacted covered entities known to be affected through Feb 28. The notice includes contact information for entities that bought Vtama at a price higher than the 340B price but that have not heard from Dermavant.
Mylan Notice About Anesthesia Drug
Separately, generic and specialty drug maker Mylan Institutional, a unit of Viatris, notified 340B entities that National Drug Code (NDC) numbers for its anesthesia drug Ultiva have changed.
“Viatris will treat each new NDC the same as the corresponding old NDC with respect to pricing and purchasing from Viatris under the 340B program,” the notice says. “Because each new Ultiva NDC represents the same product with the same 340B ceiling price as the corresponding old NDC, Viatris will permit an eligible 340B covered entity using a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities of each corresponding new NDC.”
HRSA posted Mylan’s notice last week.
